Mumbai: Russia’s Sputnik V COVID-19 vaccine that has reported 95 per cent efficacy will be much cheaper than the vaccines produced by Pfizer and Moderna.
Developed by Gamaleya Institute and RDIF (Russian Direct Investment Fund), Sputnik V’s price will be under $20 per person for a couple of doses in global markets, including India. The vaccine may be available in India by February, according to a report in The Times of India.
Sputnik V is yet to undergo trials in India and domestic companies will manufacture it. Hyderabad-based Dr Reddy’s and RDIF have collaborated to hold clinical trials and distribute the vaccine in India.
According to experts, despite the vaccine’s price advantage against Pfizer and Moderna, the main challenge could be in its distribution as it needs a specialised cooling chain.
Sputnik V vaccine’s efficacy is 91.4 per cent, on the basis of the second analysis of interim data obtained 28 days after administering the first dose (seven days after the second dose).
Preliminary data obtained 42 days after the first dose indicates an efficacy above 95%, a statement said.
Bhubaneswar: Chief Minister Naveen Patnaik on Saturday made a strong rebuttal to Prime Minister Narendra…
New Delhi: Rahul Gandhi is ready for a public debate with Narendra Modi, ‘if and…
Bhubaneswar: In a stern action against the transporters who refused to provide their vehicles for…
Mumbai: Richa Chadha has been getting a lot appreciation and praise for her performance in…
Bhubaneswar: The BJP on Saturday accused BJD of distributing money to influence the voters in…
Bhubaneswar: As the Kalinga Stadium prepares to host the prestigious 27th National Federation Senior Athletics…
Bhubaneswar: Strange is the game of politics and stranger are ways of its players. Even…
Lucknow: Comedian and politician Shyam Rangeela, who is from Rajasthan’s Hanumangarh, joined Aam Aadmi Party…